 |
7 Diseases |  |
13 Trials |
|
13 Trials |  |
1455 News |  |
| 12345678910111213...1617» |
- || Ajovy (fremanezumab-vfrm) / Teva
Clinical, Journal: Effectiveness and safety of monthly versus quarterly fremanezumab for migraine prevention: An Italian, multicenter, real-life study. (Pubmed Central) - Sep 5, 2024
Both monthly and quarterly regimens were effective and safe, with a tendency for an advantage of the monthly regimen only in the first quarter of treatment.
- || Ajovy (fremanezumab-vfrm) / Teva
Clinical, Journal: Effects of fremanezumab on migraine-associated symptoms and medication use in Japanese and Korean patients with episodic migraine: Exploratory endpoint analysis of a multicenter, randomized, double-blind, placebo-controlled trial. (Pubmed Central) - Sep 2, 2024
P2/3
Monthly and quarterly administered fremanezumab effectively prevented EM in Japanese and Korean patients. Fremanezumab also improved other disease aspects including the need for acute headache medications and the frequency of migraine-associated symptoms.
- | Journal, Machine learning: Advancing toward precision migraine treatment: Predicting responses to preventive medications with machine learning models based on patient and migraine features. (Pubmed Central) - Aug 23, 2024
We demonstrated that migraine characteristics are important in predicting treatment responses and identified the most crucial predictors for each of the seven types of preventive medications. Our results suggest that precision migraine treatment is feasible.
- | Ajovy (fremanezumab-vfrm) / Teva, Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Enrollment closed, Trial completion date, Trial primary completion date, Monotherapy: COACT Study: CGRPmAbs + OnabotulinumtoxinA Assessment of Chronic Migraine Treatments Study (clinicaltrials.gov) - Aug 20, 2024
P4, N=50, Active, not recruiting, Sponsor: Chicago Headache Center & Research Institute
Our results suggest that precision migraine treatment is feasible. Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> May 2025 | Trial primary completion date: Oct 2024 --> Mar 2025
- ||| P3 data, Retrospective data, Review, Journal: The transition of medication overuse status by acute medication categories in episodic or chronic migraine patients to non-overuse status after receiving anti-CGRP monoclonal antibodies: a systematic review and meta-analysis of phase 3 randomized control trial. (Pubmed Central) - Aug 7, 2024
Interestingly, this analysis can be interpreted as that anti-CGRP antibodies might not be effective in reducing simple analgesics use in EM or CM patients. Further studies are needed to investigate these matters.
- | Ajovy (fremanezumab-vfrm) / Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Journal: Utilisation, expenditure, and treatment patterns associated with calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) reimbursed subject to a managed access protocol in Ireland. (Pubmed Central) - Aug 4, 2024
This study demonstrates the importance of active health technology management, after reimbursement, in enabling cost-effective use of high-cost treatments while providing budget certainty for the healthcare payer. High levels of adherence and persistence suggest that treatment is successfully targeted in situations which unmet clinical need is greatest.
- || Retrospective data, Review, Journal: A Risk-Difference Meta-Analysis for the Prophylactic Treatments of Chronic Migraine. (Pubmed Central) - Jul 18, 2024
Four mAbs, namely, erenumab, fremanezumab, galcanezumab, and eptinezumab, have been marketed, although head-to-head trials with standard anti-migraine treatments are absent...The two studies of topiramate showed contradictory results, the one significant while the other not, with NNTs 2 and 22, respectively. All four anti-CGRP mAbs showed an invariably high efficacy among their studies, in terms of the ARD and its derivative measure of NNT, in contrast to oBTA, while in topiramate, the results are contradictory between the two studies.
- Ajovy (fremanezumab-vfrm) / Teva
The Effect of Fremanezumab on Pain in Patients with Complex Regional Pain Syndrome (Exhibition Hall/Poster Area) - Jul 18, 2024 - Abstract #IASP2024IASP_715;
All four anti-CGRP mAbs showed an invariably high efficacy among their studies, in terms of the ARD and its derivative measure of NNT, in contrast to oBTA, while in topiramate, the results are contradictory between the two studies. This study will hopefully elucidate the pathogenesis of CRPS, and the assessment of the efficacy of Fremanezumab may result in a mechanism-based treatment option for patients with CRPS.
- | Emgality (galcanezumab-gnlm) / Eli Lilly, Daiichi Sankyo, Organon, Ajovy (fremanezumab-vfrm) / Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Journal, Real-world evidence, Real-world: Impact of duration of chronic migraine on long-term effectiveness of monoclonal antibodies targeting the calcitonin gene-related peptide pathway-A real-world study. (Pubmed Central) - Jul 16, 2024
This study will hopefully elucidate the pathogenesis of CRPS, and the assessment of the efficacy of Fremanezumab may result in a mechanism-based treatment option for patients with CRPS. Our data showed that anti-CGRP mAbs are effective and have a rapid onset of action in CM regardless of disease duration.
- | Ajovy (fremanezumab-vfrm) / Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Observational data, Retrospective data, Journal, Real-world evidence, Real-world: Analysis to retreatment with monoclonal antibodies in chronic/episodic migraine: Real world data. (Pubmed Central) - Jul 11, 2024
Two out of three patients respond positively after restarting monoclonal therapy. This response does not appear to be related to the type of migraine, the specific monoclonal antibody prescribed, or the time to retreatment.
- | Ajovy (fremanezumab-vfrm) / Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Journal, Real-world evidence, Real-world: Analysis of retreatment with monoclonal antibodies in chronic/episodic migraine: Real world data. (Pubmed Central) - Jul 11, 2024
Two out of three patients respond positively after restarting monoclonal therapy. This response does not appear to be related to the type of migraine, the specific monoclonal antibody prescribed, or the time to retreatment.
- | Emgality (galcanezumab-gnlm) / Eli Lilly, Daiichi Sankyo, Organon, Ajovy (fremanezumab-vfrm) / Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Journal, Real-world evidence, Real-world effectiveness, Real-world: Anti?CGRP monoclonal antibodies in resistant migraine: preliminary real-world effectiveness and clinical predictors of response at two (Pubmed Central) - Jul 11, 2024
Anti-CGRP mAbs prove effectiveness and safety over a 24-month period in a RM population. Patients with no medication overuse and lower basal MMDs and MAM may respond better to anti-CGRP mAbs.
- | Ajovy (fremanezumab-vfrm) / Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Journal, HEOR: The Effect of Calcitonin Gene-Related Peptide Monoclonal Antibodies on Quality of Life among Migraine Patients: Pilot Study at the Hospital of Lithuanian University of Health Sciences Kaunas Clinics. (Pubmed Central) - Jul 9, 2024
For more than half the patients using fremanezumab or erenumab after 3-month period, MMD decreased by ?50% and total MIDAS score by >50 points. All areas of quality of life were improved after prophylactic treatment of migraine.
- | Ajovy (fremanezumab-vfrm) / Teva
Journal: Effectiveness of fremanezumab treatment in patients with migraine headache. (Pubmed Central) - Jun 18, 2024
In this real-world study of patients with migraine, fremanezumab appears to be effective and safe. Further studies are required to identify additional predictors of treatment success and failure with fremanezumab.
- Vyepti (eptinezumab-jjmr) / Teva, Lundbeck, Nurtec ODT (rimegepant ODT) / Pfizer
Combined use of rimegepant and eptinezumab for treatment of chronic migraine () - Jun 18, 2024 - Abstract #AHS2024AHS_420;
The co-administration of gepants and CGRP targeted mAbs can be effective in reducing severity and frequency of chronic migraine headaches. Patient did not report any adverse side effects from the combined use of these medications.
- Which combination of comorbidity makes migraine treatment impossible? A graphical approach () - Jun 18, 2024 - Abstract #AHS2024AHS_411;
Despite the diverse comorbidities considered, no combination of abortive or prevention medications was found to be entirely contraindicated for migraine patients. However, cardiac comorbidities such as uncontrolled hypertension or hypotension, prior coronary artery disease, and heart failure could significantly limit the possibility of abortive and preventive treatments.
- Vyepti (eptinezumab-jjmr) / Teva, Lundbeck, Ajovy (fremanezumab-vfrm) / Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
The impact and management of "wearing-off" in patients receiving calcitonin gene-related peptide pathway monoclonal antibodies for the preventive treatment of migraine () - Jun 18, 2024 - Abstract #AHS2024AHS_402;
However, physicians perceive less wearing-off with fremanezumab compared with other CGRP pathway mAbs and manage wearing-off with lifestyle or treatment changes. Further research is needed to see if these strategies for managing wearing-off can effectively address patients' symptoms and work to mitigate at least some HCRU.
- Emgality (galcanezumab-gnlm) / Eli Lilly, Daiichi Sankyo, Organon, Ajovy (fremanezumab-vfrm) / Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Real-world evidence and economic considerations of CGRP mAbs in Thailand: A retrospective analysis in middle-income countries () - Jun 18, 2024 - Abstract #AHS2024AHS_386;
Nevertheless, it is noteworthy that the cost of migraine treatment increased substantially after the initiation of CGRP mAbs, despite remaining stable thereafter. Further investigation into direct or indirect cost-utility analysis may be warranted in LMICs.
- Vyepti (eptinezumab-jjmr) / Teva, Lundbeck
Real-world effectiveness of intravenous eptinezumab in patients with chronic migraine and previous subcutaneous preventive migraine treatment () - Jun 18, 2024 - Abstract #AHS2024AHS_385;
All patients (94/94) self-reported prior preventive therapy with 89% (84/94) reporting prior subcutaneous anti-CGRP mAb use (i.e., fremanezumab, galcanezumab, or erenumab). This real-world patient survey study demonstrated that individuals with prior exposure to subcutaneous anti-CGRP monoclonal antibodies expressed high overall satisfaction with the effectiveness of eptinezumab treatment regardless of the number and type of previous therapies used.
- Qulipta (atogepant) / AbbVie
Network meta-analyses comparing the efficacy of atogepant and calcitonin gene-related peptide monoclonal antibodies on the 6-item headache impact test in individuals with migraine who were previously failed by 2 or more oral preventive migraine treatments () - Jun 18, 2024 - Abstract #AHS2024AHS_377;
This real-world patient survey study demonstrated that individuals with prior exposure to subcutaneous anti-CGRP monoclonal antibodies expressed high overall satisfaction with the effectiveness of eptinezumab treatment regardless of the number and type of previous therapies used. In patients with EM or CM who were previously failed by 2+ oral preventive migraine treatments, atogepant 60 mg once daily showed a statistically significant improvement compared with placebo, erenumab 140 mg once every month (EM), and fremanezumab 675 mg once every 3 months (CM) and a numerically but not significantly larger change from baseline in HIT-6 total score versus the other CGRP mAbs.
- Qulipta (atogepant) / AbbVie
Network meta-analyses comparing the efficacy of atogepant and calcitonin gene-related peptide monoclonal antibodies on migraine-specific quality of life in individuals with migraine who were previously failed by 2 or more oral preventive migraine treatments () - Jun 18, 2024 - Abstract #AHS2024AHS_376;
Data collected at week 12 for atogepant (60 mg once daily), fremanezumab (225 mg once every month or 675 mg once every 3 months), and galcanezumab (loading dose 240 mg followed by 120 mg once every month) were compared. Atogepant 60 mg once daily showed a significant improvement from baseline to week 12 in MSQ v2.1 RFR, RFP, and EF domain scores compared with placebo and a numerically larger improvement from baseline compared with various CGRP mAbs in individuals with EM or CM who were previously failed by 2+ oral preventive migraine treatments.
- Ajovy (fremanezumab-vfrm) / Teva
Fremanezumab effectiveness and tolerability in clinical routine: Interim real-world-data of the observational FINESSE study () - Jun 18, 2024 - Abstract #AHS2024AHS_358;
In this interim analysis of FINESSE, 53.8% of patients achieved the primary endpoint (?50% response), and reductions in MMD, disability scores and acute medication use were observed at 6 and 12 months of treatment. Tolerability data were consistent with the known safety profile of fremanezumab.
- Ajovy (fremanezumab-vfrm) / Teva
Efficacy of fremanezumab treatment for migraine prevention in patients with migraine and major depressive disorder: results from the open-label extension of the UNITE study () - Jun 18, 2024 - Abstract #AHS2024AHS_353;
Despite the complex treatment history of this high-risk population, patients with migraine and major depressive disorder experienced sustained reductions in monthly migraine days, disability, and depressive symptom scores over the OLE, suggesting that fremanezumab may reduce the symptoms and cumulative burden of both diseases. Notable reductions in these exploratory endpoints in patients who switched from placebo to fremanezumab, and in those who switched from monthly to quarterly fremanezumab dosing schedules, highlight the efficacy of both dosing regimen for migraine prevention, with safety outcomes consistent with that of the DBPC and pivotal fremanezumab randomized controlled trials.
- Emgality (galcanezumab-gnlm) / Eli Lilly, Daiichi Sankyo, Organon, Aimovig (erenumab-aooe) / Amgen, Novartis
Case report of chilblains with erenumab and galcanezumab for treatment of chronic migraine and literature review of circulation pathology associated with CGRP targeting drugs () - Jun 18, 2024 - Abstract #AHS2024AHS_333;
This case reports new onset chilblains while on two different long-acting antibody therapies, but tolerance of a receptor antagonist without side effects. These findings further substantiate the adverse event data currently published in the literature.
- Qulipta (atogepant) / AbbVie
Benefit-risk assessment based on number needed to treat and number needed to harm: Atogepant vs calcitonin gene-related peptide monoclonal antibodies () - Jun 18, 2024 - Abstract #AHS2024AHS_332;
The base- case analysis included data from core studies of atogepant 60 mg, erenumab 70 and 140 mg, galcanezumab 120 mg, eptinezumab 100 and 300 mg, and fremanezumab 225 and 675 mg. Atogepant demonstrated a favorable benefit-risk profile, with NNT and NNH values comparable with those of CGRP mAbs across all scenarios.
- Ajovy (fremanezumab-vfrm) / Teva
A comparative migraine pregnancy registry for assessing adverse maternal, fetal, and infant outcomes () - Jun 18, 2024 - Abstract #AHS2024AHS_322;
The registry (www.tevamigrainepregnancyregistry.com) is still ongoing and recruiting patients. Preliminary analysis indicated that no adverse pregnancy or infant outcomes have been reported.
- Ajovy (fremanezumab-vfrm) / Teva
6-month real-world effectiveness of fremanezumab in patients with migraine who switched from another mAb targeting the CGRP pathway (subgroup analysis from FINESSE) () - Jun 18, 2024 - Abstract #AHS2024AHS_321;
In this interim analysis of the FINESSE non-interventional study, 38.6% of anti-CGRP pathway mAb non-responders benefited (?50% response) from switching to fremanezumab. These results suggest that switching to fremanezumab may be a promising option for patients experiencing inadequate efficacy or poor tolerability with prior other anti-CGRP pathway mAb use.
- Emgality (galcanezumab-gnlm) / Eli Lilly, Daiichi Sankyo, Organon, Ajovy (fremanezumab-vfrm) / Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
The effect of calcitonin gene-related peptide monoclonal antibody switching: A tertiary-center study based on structured patient-reported outcome data () - Jun 18, 2024 - Abstract #AHS2024AHS_286;
For those who switched once, they reported greater headache burdens overall. Still, reductions in AMD and WPI were observed during mAb use.
- Vyepti (eptinezumab-jjmr) / Teva, Lundbeck
Reasons for switching from a subcutaneous calcitonin gene-related peptide receptor antagonist to intravenous eptinezumab for the preventive treatment of migraine: An observational cohort study () - Jun 18, 2024 - Abstract #AHS2024AHS_282;
Switches from SC injection CGRP mAbs were mainly driven by lack of efficacy, and the reasons for starting eptinezumab included hope for improved efficacy and to minimize the wearing-off effect. This study also found that almost two thirds (64.5%) of those who were switched to eptinezumab reported at least 75% reductions in MMDs.
- Emgality (galcanezumab-gnlm) / Eli Lilly, Daiichi Sankyo, Organon, Ajovy (fremanezumab-vfrm) / Teva
Monitoring cerebrovascular reactivity to CGRP antagonists in migraine patients measured by functional near-infrared spectroscopy () - Jun 18, 2024 - Abstract #AHS2024AHS_214;
The inclusion criteria are patients who have been diagnosed with migraine according to the definition of the International Classification of Headache Disorders 3rd edition and who have been prescribed CGRP antagonist (galcanezumab or fremanezumab) according to the approved label. fNIRS can be a useful tool for monitoring cerebral vascular reactivity to CGRP antagonists in migraine patients.
- Emgality (galcanezumab-gnlm) / Eli Lilly, Daiichi Sankyo, Organon, Ajovy (fremanezumab-vfrm) / Teva
Association between cortical thickness and response to anti-CGRP monoclonal antibodies in patients with chronic migraine () - Jun 18, 2024 - Abstract #AHS2024AHS_198;
Our analysis revealed an independent association between the cortical thickness of the left posterior cingulate cortex and the response rate to anti-CGRP mAbs in chronic migraine. This may imply the central mechanism of action of anti-CGRP mAbs despite their peripheral site of action.
- | Ajovy (fremanezumab-vfrm) / Teva
Journal, HEOR, Cost-effectiveness, Cost effectiveness: Cost Effectiveness of Fremanezumab in Episodic and Chronic Migraine Patients from a Japanese Healthcare Perspective. (Pubmed Central) - Jun 15, 2024
Using fremanezumab in a heterogeneous mixture of Japanese EM and CM patients resulted in a reduction of monthly migraine days and thus more QALYs compared with SOC. The cost effectiveness of fremanezumab versus SOC in EM and CM patients resulted in an ICER of
- || Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Clinical, Journal, HEOR, Real-world evidence, Real-world: Comparative effectiveness and tolerability of calcitonin gene-related peptide (CGRP) monoclonal antibodies and onabotulinumtoxinA in chronic migraine: A multicenter, real-world study in Taiwan. (Pubmed Central) - Jun 5, 2024
All of these injectables were well tolerated. Further prospective studies are needed to verify these findings.
- | Ajovy (fremanezumab-vfrm) / Teva, Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Journal: Results of a Web-Based Survey on 2565 Greek Migraine Patients in 2023: Demographic Data, Imposed Burden and Satisfaction to Acute and Prophylactic Treatments in the Era of New Treatment Options. (Pubmed Central) - May 25, 2024
The patients recognize the usefulness of anti-CGRP Mabs in migraine prevention and consequently seem to be more optimistic than before about living with migraine. Considering the market change that is anticipated with the use of gepants and ditans, larger longitudinal population-based studies are warranted to further explore if the new era of migraine therapeutics might further lessen the burden of the disease.
- ||| Ajovy (fremanezumab-vfrm) / Teva
Enrollment open: Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45 (clinicaltrials.gov) - May 16, 2024
P4, N=72, Recruiting, Sponsor: Brigham and Women's Hospital
Considering the market change that is anticipated with the use of gepants and ditans, larger longitudinal population-based studies are warranted to further explore if the new era of migraine therapeutics might further lessen the burden of the disease. Not yet recruiting --> Recruiting
- | Ajovy (fremanezumab-vfrm) / Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Journal: Safety considerations in the treatment with anti-CGRP(R) monoclonal antibodies in patients with migraine. (Pubmed Central) - May 14, 2024
We observed CV events in 1.6% of patients with 1.5-year follow-up of anti-CGRP(R)-mAbs treatment. We advise awareness regarding CV events in patients with migraine undergoing CGRP-targeted treatment, not as a confirmation of increased risk but as a proactive measure to address potential multifactorial influences.
- | Emgality (galcanezumab-gnlm) / Eli Lilly, Daiichi Sankyo, Organon, Ajovy (fremanezumab-vfrm) / Teva
Journal: Treatment Outcome After Switching From Galcanezumab to Fremanezumab in Patients With Migraine. (Pubmed Central) - May 7, 2024
The treatment response to fremanezumab seems to be independent of the prior treatment response to galcanezumab. Our findings suggest that switching to another anti-CGRP mAb can be considered when a particular anti-CGRP mAb is ineffective or intolerable.
- Ajovy (fremanezumab-vfrm) / Teva
Watch for John Cunningham (Poster Hall, Exhibit Hall A, Level 2) - May 6, 2024 - Abstract #ATC2024ATC_2379;
PML is extremely rare in liver transplant; only 10 cases have been reported in the literature. PML has a high mortality rate of 84% in solid organ transplant patients with median survival rate following onset of symptoms of only 6 months.
- Advancing towards precision migraine treatment: Predicting responses to preventive medications with machine learning models based on patient and migraine features (Grand Ballroom 5-9) - Apr 29, 2024 - Abstract #AHS2024AHS_90;
While employing similar methods, the model performances for other medications were less optimal, yet still clinically useful. This may be due to CGRP mAbs being migraine-specific.
- || Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Clinical, Observational data, Retrospective data, Journal, Real-world evidence, Real-world effectiveness, Real-world: Reducing the Impact of Headache and Allodynia Score in Chronic Migraine: An Exploratory Analysis from the Real-World Effectiveness of Anti-CGRP Monoclonal Antibodies Compared to Onabotulinum Toxin A (RAMO) Study. (Pubmed Central) - Apr 26, 2024
In this exploratory analysis, anti-CGRP mAbs showed superior effectiveness for HIT-6 and ASC12 compared to BoNT-A. Reductions in terms of month headache days (MHD), migraine disability assessment test (MIDAS), and migraine acute medications (MAM) were clinically relevant for both treatments.
- || PK/PD data, Review, Journal: Anti-calcitonin Gene-Related Peptide Monoclonal Antibodies in Migraine: Focus on Clinical Pharmacokinetics. (Pubmed Central) - Apr 26, 2024
Since the elimination processes do not have a large capacity, the half-life is about 2 weeks for erenumab and about 4 weeks for other monoclonal antibodies. Variability in the pharmacokinetics of these monoclonal antibodies is small in different subpopulations, and body weight is the only parameter to consider when choosing the dose of these drugs.
- || Review, Journal: Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies in Migraine: Focus on Drug Interactions. (Pubmed Central) - Apr 26, 2024
However, monoclonal antibodies may worsen diseases with already weakened CGRP neurotransmission, Raynaud phenomenon and constipation. Monoclonal antibodies used for prevention of migraine do not engage in significant pharmacokinetic interactions with other drugs; however, they do engage in pharmacodynamic interactions with other anti-migraine drugs, additively augmenting their prophylactic action, but also increasing frequency and severity of adverse reactions, which are a consequence of the CGRP neurotransmission interruption.
- || Clinical, Review, Journal: Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update. (Pubmed Central) - Apr 23, 2024
Monoclonal antibodies used for prevention of migraine do not engage in significant pharmacokinetic interactions with other drugs; however, they do engage in pharmacodynamic interactions with other anti-migraine drugs, additively augmenting their prophylactic action, but also increasing frequency and severity of adverse reactions, which are a consequence of the CGRP neurotransmission interruption. The CGRP-targeting therapies should be considered as a first-line approach for migraine prevention along with previous first-line treatments without a requirement for prior failure of other classes of migraine preventive treatment.
- ||| Emgality (galcanezumab-gnlm) / Eli Lilly, Daiichi Sankyo, Organon, Ajovy (fremanezumab-vfrm) / Teva, Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Review, Journal, Adverse events, Serious adverse event: Adverse and serious adverse events incidence of pharmacological interventions for managing chronic and episodic migraine in adults: a systematic review. (Pubmed Central) - Apr 22, 2024
All drugs showed a certain incidence of infections and infestations, with Onabotulinumtoxin A (BTA) having the lowest rate...Calcitonin gene-related peptide (CGRP) monoclonal antibodies (MAbs) such as fremanezumab and galcanezumab were linked to more general disorders and administration site conditions than other drugs...We suggest conducting head-to-head RCTs to evaluate the safety profile of oral medications, BTA, and CGRP MAbs in episodic and/or chronic migraine populations. CRD42021265993.
- | Ajovy (fremanezumab-vfrm) / Teva
Preclinical, Journal: Glycerol Trinitrate Acts Downstream of Calcitonin Gene-Related Peptide in Trigeminal Nociception-Evidence from Rodent Experiments with Anti-CGRP Antibody Fremanezumab. (Pubmed Central) - Apr 16, 2024
GTN treatment generally tends to suppress the animals' activity and increase facial sensitivity, which is partly compensated by fremanezumab through reduced CGRP signaling. If CGRP and NO signaling share the same pathway in sensitizing trigeminal afferents, GTN and NO may act downstream of CGRP to increase facial sensitivity.
- || Clinical, Review, Journal: Reporting Quality and Risk of Bias Analysis of Published RCTs Assessing Anti-CGRP Monoclonal Antibodies in Migraine Prophylaxis: A Systematic Review. (Pubmed Central) - Apr 13, 2024
Adequate reporting quality was disclosed in the evaluated RCTs with anti-CGRP MAbs in migraine prevention. However, some methodological issues need to be highlighted to be addressed in future studies assessing the efficacy of new molecules targeting CGRP or other candidate pathways implicated in migraine pathophysiology.
- | Journal: Preventive Treatment of Migraine. (Pubmed Central) - Apr 7, 2024
Six drugs targeting CGRP (four monoclonal antibodies and two gepants) are now available for the preventive treatment of episodic migraine in adults. The efficacy of CGRP-targeted medications in the acute and preventive treatment of migraine, together with good safety and tolerability, has led to the emergence of new approaches to preventive treatment.
- | Enrollment open: Migraine Medication Effects on Urinary Symptoms (clinicaltrials.gov) - Mar 29, 2024
P=N/A, N=200, Enrolling by invitation, Sponsor: The Cleveland Clinic
The efficacy of CGRP-targeted medications in the acute and preventive treatment of migraine, together with good safety and tolerability, has led to the emergence of new approaches to preventive treatment. Not yet recruiting --> Enrolling by invitation
- || Review, Journal: Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex. (Pubmed Central) - Mar 17, 2024
Available data from FDA reviews of erenumab, fremanezumab, galcanezumab and eptinezumab, approved CGRP-R and CGRP monoclonal antibodies and of atogepant were examined for prevention outcomes based on patient sex...In male and female chronic migraine patients, CGRP/CGRP-R antibodies were similarly effective. The data highlight possible differential effects of CGRP targeted therapies in different patient populations and the need for increased understanding of CGRP neurobiology in men and women.
- | Ajovy (fremanezumab-vfrm) / Teva
Journal, HEOR, Real-world evidence, Real-world: Real-world Impact of Fremanezumab on Migraine-Related Health Care Resource Utilization in Patients with Comorbidities, Acute Medication Overuse, and/or Unsatisfactory Prior Migraine Preventive Response. (Pubmed Central) - Mar 13, 2024
Patients with certain migraine comorbidities, potential AMO, and/or UPMPR in a real-world setting had reduced migraine-related medication use, HCRU, and costs following initiation of fremanezumab. Graphical abstract available for this article.